ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
Lipscombe
Lorraine L
LL
Women's College Hospital, Toronto, Ontario, Canada.